Volume 28, Number 10—October 2022
Research
SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA
Alexander C. Keyel
, Alexis Russell, Jonathan Plitnick, Jemma V. Rowlands, Daryl M. Lamson, Eli Rosenberg, and Kirsten St. George
, Alexis Russell, Jonathan Plitnick, Jemma V. Rowlands, Daryl M. Lamson, Eli Rosenberg, and Kirsten St. George
Table 3
Descriptive statistics for matched case-patients and controls for the conditional logistic regression model for study of SARS-CoV-2 vaccine breakthrough during the emergence period of the Delta variant, New York, USA*
| Demographic group | No. (%) |
||||
|---|---|---|---|---|---|
| Analysis 1, main |
Analysis 2, age |
||||
| Controls | Case-patients | Controls | Case-patients | ||
| Age, y | |||||
| 0–4 | 0 | 0 | 3 (4.5) | 0 | |
| 5–11 | 3 (5.5) | 3 (5.5) | 5 (7.6) | 0 | |
| 12–17 | 5 (9.1) | 5 (9.1) | 3 (4.5) | 4 (6.1) | |
| 18–29 | 11 (20) | 11 (20) | 12 (18.2) | 10 (15.2) | |
| 30–49 | 26 (47.3) | 26 (47.3) | 23 (34.8) | 30 (45.5) | |
| 50–69 | 6 (10.9) | 6 (10.9) | 14 (21.2) | 17 (25.8) | |
| 70–89 | 4 (7.3) | 4 (7.3) | 6 (9.1) | 5 (7.6) | |
| >90 |
0 |
0 |
0 |
0 |
|
| Sex | |||||
| M | 26 (47.3) | 25 (45.5) | 28 (42.4) | 30 (45.5) | |
| F | 29 (52.7) | 29 (52.7) | 38 (57.6) | 35 (53) | |
| Unknown |
0 |
1 (1.8) |
0 |
1 (1.5) |
|
| Region | |||||
| Capital Region | 3 (5.5) | 3 (5.5) | 4 (6.1) | 4 (6.1) | |
| Central New York | 1 (1.8) | 1 (1.8) | 1 (1.5) | 1 (1.5) | |
| Finger Lakes | 24 (43.6) | 24 (43.6) | 27 (40.9) | 27 (40.9) | |
| Long Island | 11 (20) | 11 (20) | 15 (22.7) | 15 (22.7) | |
| Mid-Hudson | 14 (25.5) | 14 (25.5) | 16 (24.2) | 16 (24.2) | |
| New York City | 0 | 0 | 1 (1.5) | 1 (1.5) | |
| North Country | 0 | 0 | 0 | 0 | |
| Southern Tier | 1 (1.8) | 1 (1.8) | 1 (1.5) | 1 (1.5) | |
| Western New York |
1 (1.8) |
1 (1.8) |
1 (1.5) |
1 (1.5) |
|
| Vaccination status | |||||
| Unvaccinated | 41 (74.5) | 34 (61.8) | 48 (72.7) | 35 (53) | |
| Vaccinated <90 d | 7 (12.7) | 9 (16.4) | 9 (13.6) | 9 (13.6) | |
| Vaccinated >90 d | 7 (12.7) | 12 (21.8) | 9 (13.6) | 22 (33.3) | |
| Pfizer vaccine | 10 (18.2) | 18 (32.7) | 11 (16.7) | 28 (42.4) | |
| Moderna vaccine | 5 (9.1) | 2 (3.6) | 4 (6.1) | 3 (4.5) | |
| Janssen vaccine | 1 (1.8) | 3 (5.5) | 3 (4.5) | 1 (1.5) | |
*Presence (case-patient) or absence (control) of Omicron was used as the basis for matching. Janssen vaccine, Janssen/Johnson & Johnson (https://www.jnj.com); Pfizer vaccine, Pfizer-BioNTech (https://www.pfizer.com); Moderna vaccine, Moderna (https://www.modernatx.com).
Page created: August 25, 2022
Page updated: September 20, 2022
Page reviewed: September 20, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.